Swedbank AB Boosts Holdings in Axon Enterprise, Inc $AXON

Swedbank AB grew its position in Axon Enterprise, Inc (NASDAQ:AXON) by 1.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 110,683 shares of the biotechnology company’s stock after buying an additional 1,820 shares during the period. Swedbank AB owned 0.14% of Axon Enterprise worth $62,860,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Evergreen Capital Management LLC grew its stake in shares of Axon Enterprise by 3.8% in the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after buying an additional 15 shares during the period. NorthCrest Asset Manangement LLC grew its stake in shares of Axon Enterprise by 5.4% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 16 shares during the period. Monte Financial Group LLC grew its stake in shares of Axon Enterprise by 5.5% in the 3rd quarter. Monte Financial Group LLC now owns 325 shares of the biotechnology company’s stock valued at $233,000 after buying an additional 17 shares during the period. Wealth Alliance LLC grew its stake in shares of Axon Enterprise by 3.2% in the 3rd quarter. Wealth Alliance LLC now owns 583 shares of the biotechnology company’s stock valued at $419,000 after buying an additional 18 shares during the period. Finally, Commerzbank Aktiengesellschaft FI grew its stake in shares of Axon Enterprise by 4.5% in the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 439 shares of the biotechnology company’s stock valued at $316,000 after buying an additional 19 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Wall Street Analysts Forecast Growth

AXON has been the subject of several analyst reports. TD Cowen dropped their price target on shares of Axon Enterprise from $950.00 to $825.00 and set a “buy” rating for the company in a research note on Wednesday, April 8th. Zacks Research raised shares of Axon Enterprise from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. Barclays dropped their price target on shares of Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Needham & Company LLC lowered their price objective on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Finally, Morgan Stanley set a $600.00 price objective on shares of Axon Enterprise in a research report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $712.75.

Insider Activity

In related news, insider Isaiah Fields sold 2,000 shares of the stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $535.01, for a total transaction of $1,070,020.00. Following the completion of the transaction, the insider owned 55,588 shares of the company’s stock, valued at approximately $29,740,135.88. This trade represents a 3.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jeri Williams sold 157 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $490.00, for a total transaction of $76,930.00. Following the sale, the director owned 1,159 shares in the company, valued at approximately $567,910. This trade represents a 11.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 13,855 shares of company stock worth $7,109,828 in the last three months. 4.20% of the stock is currently owned by corporate insiders.

Axon Enterprise Stock Performance

NASDAQ:AXON opened at $386.00 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27. The stock has a market capitalization of $31.11 billion, a P/E ratio of 155.02, a PEG ratio of 7.02 and a beta of 1.44. The company has a 50 day moving average price of $416.52 and a 200 day moving average price of $503.10. Axon Enterprise, Inc has a fifty-two week low of $339.01 and a fifty-two week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. The firm had revenue of $807.35 million during the quarter, compared to analysts’ expectations of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The firm’s quarterly revenue was up 33.7% on a year-over-year basis. During the same quarter last year, the company posted $1.47 EPS. Equities research analysts forecast that Axon Enterprise, Inc will post 1.82 EPS for the current year.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.